. Author manuscript; available in PMC: 2012 Mar 1.

Published in final edited form as: Am J Obstet Gynecol. 2010 Dec 17;204(3):211.e1–211.e6. doi: 10.1016/j.ajog.2010.10.898

Table 2.

Primary outcome, as defined by Nugent criteria, after completion of therapy by randomized treatment group (N (%))

Nugent Score	Metronidazole	Tinidazole 1 gm	Tinidazole 500mg	P value
14 day follow-up visit
≥7	24/136 (17.7)	37/137 (27.0)	36/146 (24.7)	0.16
				0.19^*
<7	112/136 (82.4)	100/137 (73.0)	110/146 (75.3)	0.08⁺
1 month follow-up visit
≥7	42/117 (35.9)	37/114 (32.5)	45/118 (38.1)	0.66
7	75/117 (64.1)	77/114 (67.5)	73/118 (61.9)

P values are for the comparison of all three groups unless otherwise marked

p value for metronidazole versus tinidazole 500 mg

⁺

pvalue for metronidazole versus tinidazole 1 gm